• Jobs
  • Startups
  • Hire
LoginSign up
Organization banner

Role description

Senior Research Associate, Assay Development - PM Shift (Contract)

Delfi logoDelfi
TypeContract
WorkplaceOn-site
SenioritySenior
Salary$52–$63/hr
LocationPalo Alto, CA
Posted10/23/2026
Research

DELFI Diagnostics, Inc. (DELFI Diagnostics) is developing next-generation, blood-based tests that are reliable, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI ("DNA EvaLuation of Fragments for early Interception") platform is built to address the highest-burden health challenges. DELFI Diagnostics prioritizes solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI Diagnostics’ platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is DELFI Diagnostics’ first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA.

In our passionate pursuit to radically improve health outcomes, we serve humanity when we:

  • Lead with Science, Anchor in Pragmatism: We pioneer life-changing science by ensuring quality, transparency, and rigor at all times. We explore thoughtfully, experiment smartly, and deliver impact with conviction.

  • Build With & For All: We embrace diverse backgrounds to innovate and achieve together. We are not just building a product - we aim to disrupt the path of cancer for all - no matter geography or socioeconomic class 

  • Put We over I: We are a home for high-performing people. Through teamwork, we build collective intelligence. Each of us wins when those we serve and those who serve with us--win. We show up with empathy, humility, and integrity at every step of the journey.

What You'll Do

    As Sr. Research Associate, you will play a critical role in developing and validating next-generation sequencing assays from concept through commercial launch, working within a collaborative environment of scientists, engineers, and bioinformaticians. You will contribute to product development, verification, and validation activities for NGS-based laboratory tests for early cancer detection. The ideal candidates would have experience working under Good Laboratory Practice (GLP) in a CAP/CLIA/FDA-regulated environment.

    Contribute to the success of a cohesive, innovative, motivated team that is dedicated to reducing cancer deaths through the following activities:

  • Design, execute, and troubleshoot moderate to complex laboratory experiments utilizing molecular biology techniques for Next-Generation Sequencing (NGS).

  • Perform end-to-end experimental workflows, including nucleic acid extraction, library preparation, and sequencing, while preparing samples and executing experiments with meticulous attention to detail and adherence to high-quality standards.

  • Communicate findings effectively with multidisciplinary teams, including biologists, bioinformaticians, statisticians, automation engineers, and quality control scientists, and present at scientific meetings.

  • Contribute to advancing assays through design control processes to meet product requirements and regulatory standards by maintaining comprehensive documentation.

What You'll Bring

    Required:

  • BS with 3-4 years of experience, or MS with 2-3 years relevant field (e.g., biomedical engineering, molecular biology, genetics, or genomics) in assay development for the life science industry

  • Ability to work day shift 7:30AM - 4PM during training and then PM shift 4PM to 12AM for up to 3 months during  January - March 

  • Proven ability to thoughtfully troubleshoot, communicate and escalate while working with limited support on a PM shift

  • Proficient in high-throughput manual laboratory techniques, including precision pipetting for large-scale sample processing

  • Proven track record in laboratory NGS execution and addressing technical challenges specific to nucleic acid extraction and library preparation for NGS

  • Strong analytical skills with demonstrated ability to work independently

  • Superior organizational and project management abilities, including meticulous documentation practices, strategic planning, and effective time management with keen attention to detail

  • Preferred:

  • Hands-on experience with automated liquid handling systems for assay development and execution

  • Experience troubleshooting and communicating issues

  • Advanced data analysis skills using Excel and statistical software packages; programming experience in Python, R or similar languages is highly valued

  • Direct experience in a regulated environment (CLIA, CAP, NYS, FDA, GXP, etc.)

We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.

Relevant archetypes

Apply on Lever
Save

Company info

Delfi logo

Delfi

DELFI Diagnostics is developing next-generation, blood-based tests that are convenient, accessible, and reliable, offering a new way to help detect cancer. DELFI's proprietary technology leverages advanced AI to analyze patterns of circulating cell-free DNA fragments in the blood, an approach known as fragmentomics, to help detect lung cancer with high sensitivity. FirstLook Lung, the first commercially available blood-based screening test for lung cancer in the United States, serves individuals eligible for lung cancer screening through a simple blood draw that integrates with routine blood work. With a negative predictive value of 99.8 percent, the test identifies individuals at elevated risk for lung cancer, including early-stage disease, and guides them toward follow-up with guideline-recommended low-dose CT. Through novel health system partnerships, DELFI is pioneering electronic medical record (EMR) integration that makes blood-based testing available to historically underserved

Founded2019
HQPalo Alto, United States
Size51–200 employees
Unlock human wisdom
ThesisTermsPrivacy
Industry
Medical and Diagnostic Laboratories
Investors
DFJ Growth

Claim delfidiagnostics.com

Work at delfidiagnostics.com? Sign in to claim this org and manage its profile.

© 2026 Saywise Inc.